Get started
Author

Emmanuelle Malaurie

Expression of the genetic variants of human alpha-1-acid glycoprotein in cancer
2000 · Jean-Claude Duché, Saïk Urien, et al. · Clinical Biochemistry · 88
Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer
2021 · Claire Falandry, Frédérique Rousseau, et al. · JAMA Oncology · 82
PDF
Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Propeukin Program Cooperative Group.
1998 · J M Tourani, C Pfister, et al. · Journal of Clinical Oncology · 75
Randomized clinical trial of post-operative radiotherapy versus concomitant carboplatin and radiotherapy for head and neck cancers with lymph node involvement
2008 · Séverine Racadot, Mariette Mercier, et al. · Radiotherapy and Oncology · 44
A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer
2023 · Félix Blanc-Durand, Elisa Yaniz-Galende, et al. · Gynecologic Oncology · 36
Tumors of the heart and great vessels
1998 · E. Malaurie, C. Petitjean, et al. · Springer eBooks · 26
Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial
2023 · Gwénaël Ferron, Gaëtan De Rauglaudre, et al. · Gynecologic Oncology · 24
Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial
2025 · Etienne Brain, Olivier Mir, et al. · The Lancet · 23
Role of lipoproteins in the plasma binding of SDZ PSC 833, a novel multidrug resistance‐reversing cyclosporin
1998 · Nicolas Simon, Eric Dailly, et al. · British Journal of Clinical Pharmacology · 23
PDF
Epirubicin/paclitaxel/carboplatin (TEC) vs paclitaxel/carboplatin (TC) in first-line treatment of ovarian cancer (OC) FIGO stages IIB–IV. An AGO-GINECO Intergroup phase III trial
2004 · A. du Bois, M. Combe, et al. · Journal of Clinical Oncology · 20
Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study)
2020 · Patrick Robelin, Michel Tod, et al. · Gynecologic Oncology · 19
PDF
Evaluation of a RAD51 functional assay in advanced ovarian cancer, a GINECO/GINEGEPS study.
2021 · Felix Blanc-Durand, Elisa Yaniz, et al. · Journal of Clinical Oncology · 18
The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research
2024 · Aurélie Moniot, Christophe Schneider, et al. · Molecular Cancer · 17
PDF
Impact of adding nintedanib to neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer (EOC) patients: The CHIVA double-blind randomized phase II GINECO study.
2019 · Gwenael Ferron, Gaetan De Rauglaudre, et al. · Journal of Clinical Oncology · 16
Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients
2021 · Dominique Berton, Anne Floquet, et al. · Frontiers in Pharmacology · 14
PDF
Tumors of the gastrointestinal tract
1998 · B. Chiche, E. Malaurie, et al. · Springer eBooks · 14
Afatinib maintenance therapy following post-operative radiochemotherapy in head and neck squamous cell carcinoma: Results from the phase III randomised double-blind placebo-controlled study BIB2992ORL (GORTEC 2010–02)
2022 · Séverine Racadot, Isabelle Thennevet, et al. · European Journal of Cancer · 13
Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
2024 · Elisa Yaniz-Galende, Qinghe Zeng, et al. · Clinical Cancer Research · 12
PDF
Phase I study of Datelliptium chloride, hydrochloride given by 24-h continuous intravenous infusion
1992 · D. Khayat, C. Borel, et al. · Cancer Chemotherapy and Pharmacology · 12
5-year results of hypofractionated locoregional radiotherapy in early breast cancer HypoG-01 (UNICANCER): a French multicentre, randomised, non-inferiority, phase 3, open-label, controlled trial
2026 · Sofia Rivera, Robabeh Ghodssighassemabadi, et al. · The Lancet · 11
Prognostic value of circulating tumor DNA at diagnosis and its early decrease after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer. An ancillary analysis of the CHIVA phase II GINECO trial
2024 · Henri Azaïs, Camille Brochard, et al. · Gynecologic Oncology · 7
PDF
HER2 status in urothelial bladder cancer (UC): screening of patients eligible for a phase II randomized study of gemcitabine plus platinum salt with or without trastuzumab
2005 · A. Vieillefond, P. Beuzeboc, et al. · Journal of Clinical Oncology · 6
A randomized study of CDDP and 5-FU as Neo-Adjuvant chemotherapy in head and neck cancer: an interim analysis
1994 · M. Martin, L. Vergnes, et al. · Cancer Treatment An Update · 6
Comprehensive radiotherapy quality assurance analysis from individual DICOM data in the HypoG-01 phase 3 trial
2025 · Thomas Brion, Mamadou Balde, et al. · Radiotherapy and Oncology · 5
Correlation Between Electronic Patient-Reported Outcomes and Biological Markers of Key Parameters in Acute Radiation Cystitis Among Patients With Prostate Cancer (RABBIO): Prospective Observational Study
2024 · Carole Helissey, Sophie Cavallero, et al. · JMIR Cancer · 4
PDF
Works count: 74
Citation count: 630
H-index: 14
I10-index: 20
Year
Topic
Type